Pay in 4 interest-free payments of $6.88 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
Alcohol Research & Health , 23 (1), 40-54.
Key comparative insights from the benzimidazole class: All benzimidazoles share CYP450-dependent hepatic metabolism, creating a common vulnerability pathway Hepatotoxicity risk across the class is dose-dependent and duration-dependent consistent with the fenbendazole case reports Hepatotoxicity is generally reversible upon discontinuation across all benzimidazoles also consistent with fenbendazole data The mechanism appears to involve both direct metabolite toxicity and immune-mediated components, particularly when combined with immunomodulatory agents Veterinary safety data for fenbendazole shows remarkable tolerability: studies in dogs have documented safety margins of 100 the standard dose without significant hepatotoxicity, suggesting that the human cases represent an uncommon susceptibility pattern rather than inherent high toxicity This class-level perspective reinforces that fenbendazole's hepatotoxic risk is real but predictable, dose-related, and manageable with appropriate monitoring consistent with the safety profile of related compounds that have decades of human clinical use data
Question 1: Is FDA-approved medication non-negotiable for you
Supporting Study: Wren, A
For people with cirrhosis or liver disease: Dont take acarbose if you have cirrhosis or severe liver disease
At 10 mg, average weight loss jumped to 21.4%, roughly 47 pounds from the same starting weight
